Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib

IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the nega...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sobotta, Svantje (VerfasserIn) , Lehmann, Wolf-Dieter (VerfasserIn) , Gretz, Norbert (VerfasserIn) , Schilling, Marcel (VerfasserIn) , Klingmüller, Ursula (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 09 October 2017
In: Frontiers in physiology
Year: 2017, Jahrgang: 8
ISSN:1664-042X
DOI:10.3389/fphys.2017.00775
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.3389/fphys.2017.00775
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fphys.2017.00775/full
Volltext
Verfasserangaben:Svantje Sobotta, Andreas Raue, Xiaoyun Huang, Joep Vanlier, Anja Jünger, Sebastian Bohl, Ute Albrecht, Maximilian J. Hahnel, Stephanie Wolf, Nikola S. Mueller, Lorenza A. D'Alessandro, Stephanie Mueller-Bohl, Martin E. Boehm, Philippe Lucarelli, Sandra Bonefas, Georg Damm, Daniel Seehofer, Wolf D. Lehmann, Stefan Rose-John, Frank van der Hoeven, Norbert Gretz, Fabian J. Theis, Christian Ehlting, Johannes G. Bode, Jens Timmer, Marcel Schilling and Ursula Klingmüller

MARC

LEADER 00000caa a2200000 c 4500
001 1580443923
003 DE-627
005 20230427065700.0
007 cr uuu---uuuuu
008 180828s2017 xx |||||o 00| ||eng c
024 7 |a 10.3389/fphys.2017.00775  |2 doi 
035 |a (DE-627)1580443923 
035 |a (DE-576)510443923 
035 |a (DE-599)BSZ510443923 
035 |a (OCoLC)1341017665 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sobotta, Svantje  |e VerfasserIn  |0 (DE-588)1165593092  |0 (DE-627)1029655472  |0 (DE-576)510443761  |4 aut 
245 1 0 |a Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib  |c Svantje Sobotta, Andreas Raue, Xiaoyun Huang, Joep Vanlier, Anja Jünger, Sebastian Bohl, Ute Albrecht, Maximilian J. Hahnel, Stephanie Wolf, Nikola S. Mueller, Lorenza A. D'Alessandro, Stephanie Mueller-Bohl, Martin E. Boehm, Philippe Lucarelli, Sandra Bonefas, Georg Damm, Daniel Seehofer, Wolf D. Lehmann, Stefan Rose-John, Frank van der Hoeven, Norbert Gretz, Fabian J. Theis, Christian Ehlting, Johannes G. Bode, Jens Timmer, Marcel Schilling and Ursula Klingmüller 
264 1 |c 09 October 2017 
300 |a 25 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.08.2018 
520 |a IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential equations (ODE) and the model parameters were estimated by a maximum likelihood approach, whereas identifiability of the dynamic model parameters was ensured by the Profile Likelihood. Using model simulations coupled with experimental validation we could optimize the long-term impact of the JAK-inhibitor Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted doses and timing of treatments helps to improve the reduction of inflammatory APP gene expression in primary mouse hepatocytes close to levels observed during regenerative conditions. The concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes. Thus, combining quantitative data generation with mathematical modeling suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines. 
650 4 |a acute phase response 
650 4 |a IL-6 
650 4 |a JAK/STAT signaling pathway 
650 4 |a mathematical modeling 
650 4 |a ODE models 
650 4 |a primary hepatocytes 
650 4 |a Ruxolitinib 
700 1 |a Lehmann, Wolf-Dieter  |d 1948-  |e VerfasserIn  |0 (DE-588)1119825083  |0 (DE-627)872907716  |0 (DE-576)174059973  |4 aut 
700 1 |a Gretz, Norbert  |d 1954-2023  |e VerfasserIn  |0 (DE-588)1020104589  |0 (DE-627)691105154  |0 (DE-576)359544843  |4 aut 
700 1 |a Schilling, Marcel  |d 1977-  |e VerfasserIn  |0 (DE-588)13305120X  |0 (DE-627)533308321  |0 (DE-576)265224136  |4 aut 
700 1 |a Klingmüller, Ursula  |d 1964-  |e VerfasserIn  |0 (DE-588)1098573455  |0 (DE-627)857742876  |0 (DE-576)46917014X  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in physiology  |d Lausanne : Frontiers Research Foundation, 2007  |g 8(2017) Artikel-Nummer 775, 25 Seiten  |h Online-Ressource  |w (DE-627)631498788  |w (DE-600)2564217-0  |w (DE-576)32655095X  |x 1664-042X  |7 nnas  |a Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib 
773 1 8 |g volume:8  |g year:2017  |g extent:25  |a Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib 
856 4 0 |u http://dx.doi.org/10.3389/fphys.2017.00775  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fphys.2017.00775/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180828 
993 |a Article 
994 |a 2017 
998 |g 1098573455  |a Klingmüller, Ursula  |m 1098573455:Klingmüller, Ursula  |d 140000  |e 140000PK1098573455  |k 0/140000/  |p 27  |y j 
998 |g 13305120X  |a Schilling, Marcel  |m 13305120X:Schilling, Marcel  |d 700000  |d 706000  |e 700000PS13305120X  |e 706000PS13305120X  |k 0/700000/  |k 1/700000/706000/  |p 26 
998 |g 1020104589  |a Gretz, Norbert  |m 1020104589:Gretz, Norbert  |d 60000  |d 999811  |e 60000PG1020104589  |e 999811PG1020104589  |k 0/60000/  |k 1/60000/999811/  |p 21 
998 |g 1119825083  |a Lehmann, Wolf-Dieter  |m 1119825083:Lehmann, Wolf-Dieter  |d 50000  |e 50000PL1119825083  |k 0/50000/  |p 18 
999 |a KXP-PPN1580443923  |e 3024043209 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Svantje Sobotta, Andreas Raue, Xiaoyun Huang, Joep Vanlier, Anja Jünger, Sebastian Bohl, Ute Albrecht, Maximilian J. Hahnel, Stephanie Wolf, Nikola S. Mueller, Lorenza A. D'Alessandro, Stephanie Mueller-Bohl, Martin E. Boehm, Philippe Lucarelli, Sandra Bonefas, Georg Damm, Daniel Seehofer, Wolf D. Lehmann, Stefan Rose-John, Frank van der Hoeven, Norbert Gretz, Fabian J. Theis, Christian Ehlting, Johannes G. Bode, Jens Timmer, Marcel Schilling and Ursula Klingmüller"]},"title":[{"title_sort":"Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib","title":"Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinib"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"family":"Sobotta","role":"aut","display":"Sobotta, Svantje","given":"Svantje"},{"role":"aut","display":"Lehmann, Wolf-Dieter","family":"Lehmann","given":"Wolf-Dieter"},{"given":"Norbert","display":"Gretz, Norbert","role":"aut","family":"Gretz"},{"family":"Schilling","role":"aut","display":"Schilling, Marcel","given":"Marcel"},{"given":"Ursula","family":"Klingmüller","display":"Klingmüller, Ursula","role":"aut"}],"id":{"eki":["1580443923"],"doi":["10.3389/fphys.2017.00775"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"09 October 2017"}],"language":["eng"],"note":["Gesehen am 28.08.2018"],"relHost":[{"id":{"issn":["1664-042X"],"eki":["631498788"],"zdb":["2564217-0"]},"part":{"text":"8(2017) Artikel-Nummer 775, 25 Seiten","year":"2017","volume":"8","extent":"25"},"origin":[{"publisher":"Frontiers Research Foundation","publisherPlace":"Lausanne","dateIssuedKey":"2007","dateIssuedDisp":"2007-"}],"disp":"Model based targeting of IL-6-induced inflammatory responses in cultured primary hepatocytes to improve application of the JAK inhibitor ruxolitinibFrontiers in physiology","title":[{"title":"Frontiers in physiology","title_sort":"Frontiers in physiology"}],"name":{"displayForm":["Frontiers Research Foundation"]},"pubHistory":["2007 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"631498788","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 24.05.23"]}],"recId":"1580443923","physDesc":[{"extent":"25 S."}]} 
SRT |a SOBOTTASVAMODELBASED0920